Bill Nygren released his Oakmark Fund second quarter portfolio earlier today which reported a total of 53 stocks valued at over $9.06 billion. Nygren purchased three new stocks and increased his position in 29 over the duration of the second quarter.
The following stocks represent the holdings Nygren made the largest increases to throughout the second quarter.
Nygren’s Top Five Increases
Forest Laboratories (FRX)
During the second quarter, Nygren increased his holdings in Forest Laboratories by 65%. The guru purchased a total of 1,950,000 shares in the second quarter price range of $35.44 to $41.84, with an estimated average price of $38.64. Since then the price per share has increased about 10.2%.
Nygren now owns a total of 4.95 million shares of Forest Laboratories, representing 1.86% of the company’s shares outstanding and 2.2% of his total portfolio.
Nygren’s holding history as of the second quarter:
The company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription.
Forest Laboratories’ historical revenue and net income:
Forest Laboratories has a market cap of $11.44 billion. Its shares are currently trading at around $42.60 with a P/E ratio of 98.70, a P/S ratio of 3.60 and a P/B ratio of 1.90.
McDonald’s (MCD)
Nygren upped his stake in McDonald’s by 62.57% during the second quarter. The guru purchased a total of 600,000 shares in the price range of $96.42 to $103.59, with an estimated average price of $100.14 per share. Since then the share price is down about -4.6%.
Nygren now holds on to a total of 1,559,000 shares of McDonald’s, representing 0.16% of the company’s shares outstanding and 1.7% of his total portfolio.
Nygren’s holding history as of the second quarter:
The company franchises and operates McDonald's restaurants in the food service industry.
McDonald’s historical revenue and net income:
The Peter Lynch Chart suggests that McDonald’s is currently overvalued:
McDonald’s has a market cap of $95.46 billion. Its shares are currently trading at around $95.49 with a P/E ratio of 17.50, a P/S ratio of 3.50 and a P/B ratio of 6.30. The company had an annual average earnings growth of 14.4% over the past ten years.
GuruFocus rated McDonald’s the business predictability rank of 5-star.
Devon Energy (DVN)
During the second quarter Nygren increased his position in Devon Energy by 34.22%. The guru purchased 960,000 shares in the price range of $51.44 to $60.17. As of the second quarter, Nygren holds on to a total of 3,765,000 shares of Devon, representing 0.93% of the company’s shares outstanding and 2.2% of his total portfolio.
The Company is an independent energy company engaged mainly in the exploration, development and production of oil, natural gas and NGLs. The Company's operations are concentrated in various North American onshore areas in the U.S. and Canada.
Devon Energy’s historical revenue and earnings growth:
Devon Energy has a market cap of $22.9 billion. Its shares are currently trading at around $56.40 with a P/E ratio of 32.80, a P/S ratio of 2.40 and a P/B ratio of 1.20. The company has a 1.50% dividend yield.
Halliburton (HAL)
During the second quarter Nygren increased his position in Halliburton by 25%. The guru purchased a total of 800,000 shares in the second quarter price range of $37.21 to $45.55, with an estimated average price of $41.80. Since then the price per share has increased approximately 13.3%.
Nygren now holds on to 4 million shares of Halliburton, representing 0.43% of the company’s shares outstanding and 1.8% of his total portfolio.
Nygren’s holding history as of the second quarter:
[/url]
The Company is a provider of services and products to the energy industry related to the exploration, development, and production of oil and natural gas. It serves major, national, and independent oil and natural gas companies throughout the world.
Halliburton’s historical revenue and net income:
The Peter Lynch Chart shows that Halliburton currently appears to be overvalued:
Halliburton has a market cap of $43.03 billion. Its shares are currently trading at around $47.10 with a P/E ratio of 24.00, a P/S ratio of 1.50 and a P/B ratio of 2.90. The company had an annual average earnings growth of 16.5% over the past ten years.
Covidien PLC (COV)
During the second quarter Nygren increased his holdings in Covidien by 23.5%. The guru bought a total of 500,000 shares in the price range of $56.41 to $62.41, with an estimated average price of $59.39 per share. Since then the price per share has increased approximately 2%.
Nygren now holds on to 2,628,000 shares of Covidien, representing 0.56% of the company’s shares outstanding and 1.8% of his total portfolio.
Nygren’s holding history of Covidien as of the second quarter:
[/url]
The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company operates its business through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies.
Covidien’s historical revenue and net income:
The Peter Lynch Chart suggests that the company is currently overvalued:
Covidien has a market cap of $27.86 billion. Its shares are currently trading at around $60.56 with a P/E ratio of 15.10, a P/S ratio of 2.40 and a P/B ratio of 3.00. The company had an annual average earnings growth of 5.4% over the past ten years.
Check out Bill Nygren’s second quarter Oakmark portfolio here.
Try a free 7-day premium membership here.
The following stocks represent the holdings Nygren made the largest increases to throughout the second quarter.
Nygren’s Top Five Increases
Forest Laboratories (FRX)
During the second quarter, Nygren increased his holdings in Forest Laboratories by 65%. The guru purchased a total of 1,950,000 shares in the second quarter price range of $35.44 to $41.84, with an estimated average price of $38.64. Since then the price per share has increased about 10.2%.
Nygren now owns a total of 4.95 million shares of Forest Laboratories, representing 1.86% of the company’s shares outstanding and 2.2% of his total portfolio.
Nygren’s holding history as of the second quarter:
The company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription.
Forest Laboratories’ historical revenue and net income:
Forest Laboratories has a market cap of $11.44 billion. Its shares are currently trading at around $42.60 with a P/E ratio of 98.70, a P/S ratio of 3.60 and a P/B ratio of 1.90.
McDonald’s (MCD)
Nygren upped his stake in McDonald’s by 62.57% during the second quarter. The guru purchased a total of 600,000 shares in the price range of $96.42 to $103.59, with an estimated average price of $100.14 per share. Since then the share price is down about -4.6%.
Nygren now holds on to a total of 1,559,000 shares of McDonald’s, representing 0.16% of the company’s shares outstanding and 1.7% of his total portfolio.
Nygren’s holding history as of the second quarter:
The company franchises and operates McDonald's restaurants in the food service industry.
McDonald’s historical revenue and net income:
The Peter Lynch Chart suggests that McDonald’s is currently overvalued:
McDonald’s has a market cap of $95.46 billion. Its shares are currently trading at around $95.49 with a P/E ratio of 17.50, a P/S ratio of 3.50 and a P/B ratio of 6.30. The company had an annual average earnings growth of 14.4% over the past ten years.
GuruFocus rated McDonald’s the business predictability rank of 5-star.
Devon Energy (DVN)
During the second quarter Nygren increased his position in Devon Energy by 34.22%. The guru purchased 960,000 shares in the price range of $51.44 to $60.17. As of the second quarter, Nygren holds on to a total of 3,765,000 shares of Devon, representing 0.93% of the company’s shares outstanding and 2.2% of his total portfolio.
The Company is an independent energy company engaged mainly in the exploration, development and production of oil, natural gas and NGLs. The Company's operations are concentrated in various North American onshore areas in the U.S. and Canada.
Devon Energy’s historical revenue and earnings growth:
Devon Energy has a market cap of $22.9 billion. Its shares are currently trading at around $56.40 with a P/E ratio of 32.80, a P/S ratio of 2.40 and a P/B ratio of 1.20. The company has a 1.50% dividend yield.
Halliburton (HAL)
During the second quarter Nygren increased his position in Halliburton by 25%. The guru purchased a total of 800,000 shares in the second quarter price range of $37.21 to $45.55, with an estimated average price of $41.80. Since then the price per share has increased approximately 13.3%.
Nygren now holds on to 4 million shares of Halliburton, representing 0.43% of the company’s shares outstanding and 1.8% of his total portfolio.
Nygren’s holding history as of the second quarter:
[/url]The Company is a provider of services and products to the energy industry related to the exploration, development, and production of oil and natural gas. It serves major, national, and independent oil and natural gas companies throughout the world.
Halliburton’s historical revenue and net income:
The Peter Lynch Chart shows that Halliburton currently appears to be overvalued:
Halliburton has a market cap of $43.03 billion. Its shares are currently trading at around $47.10 with a P/E ratio of 24.00, a P/S ratio of 1.50 and a P/B ratio of 2.90. The company had an annual average earnings growth of 16.5% over the past ten years.
Covidien PLC (COV)
During the second quarter Nygren increased his holdings in Covidien by 23.5%. The guru bought a total of 500,000 shares in the price range of $56.41 to $62.41, with an estimated average price of $59.39 per share. Since then the price per share has increased approximately 2%.
Nygren now holds on to 2,628,000 shares of Covidien, representing 0.56% of the company’s shares outstanding and 1.8% of his total portfolio.
Nygren’s holding history of Covidien as of the second quarter:
[/url]The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company operates its business through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies.
Covidien’s historical revenue and net income:
The Peter Lynch Chart suggests that the company is currently overvalued:
Covidien has a market cap of $27.86 billion. Its shares are currently trading at around $60.56 with a P/E ratio of 15.10, a P/S ratio of 2.40 and a P/B ratio of 3.00. The company had an annual average earnings growth of 5.4% over the past ten years.
Check out Bill Nygren’s second quarter Oakmark portfolio here.
Try a free 7-day premium membership here.
